Patterson Companies, Inc. successfully completed its acquisition by Patient Square Capital, on April 17, 2025. As a result of this transaction, Patterson?s common stock is no longer traded on the NASDAQ Global Select Market. In conjunction with the closing of the acquisition, Patterson announced the appointment of Robert Rajalingam as the new Chief Executive Officer of Patterson.
Don Zurbay, who previously served as CEO, will be retiring and will continue to support the Company on a transitional basis. Mr. Rajalingam has more than 25 years of experience in health care management, most recently as President of Cardinal Health?s US Medical Products and Distribution business, where he led a significant transformation in the business. Mr. Rajalingam has also held leadership roles at Smiths Medical, Medtronic, Covidien, and Lilly.
Prior to joining Patterson Companies, Mr. Rajalingam was a member of Cardinal Health's Operating Committee, where he led the resurgence of the US Medical Products and Distribution business while successfully navigating national COVID response efforts, a significant FDA recall, global supply chain constraints, and hyperinflation. From the onset of the pandemic, he served on the White House Supply Chain advisory council, advising HHS, FEMA, DLA, and White House senior leadership. Prior to Cardinal Health, Robert held leadership positions at Medtronic, Covidien, and Smiths Medical, exceeding performance targets and driving shareholder value.
Robert holds bachelor?s degrees in biomedical engineering and economics from Duke University and a Master of Business Administration from Stanford University?s Graduate School of Business.
